Biomarkers of Acute Lung Injury The Individualized Approach: for Phenotyping, Risk Stratification and Treatment Surveillance

Do we need biomarkers of lung damage and infection: For what purpose and how should they be used properly? Biomarkers of lung damage can be used for diagnosis, risk stratification/prediction, treatment surveillance and adjustment of targeted therapy. Additionally, novel "omics" methods may...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical medicine 2019-08, Vol.8 (8), p.1163
Hauptverfasser: Murray, Daniel D, Itenov, Theis Skovsgaard, Sivapalan, Pradeesh, Eklöf, Josefin Viktoria, Holm, Freja Stæhr, Schuetz, Philipp, Jensen, Jens Ulrik
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 8
container_start_page 1163
container_title Journal of clinical medicine
container_volume 8
creator Murray, Daniel D
Itenov, Theis Skovsgaard
Sivapalan, Pradeesh
Eklöf, Josefin Viktoria
Holm, Freja Stæhr
Schuetz, Philipp
Jensen, Jens Ulrik
description Do we need biomarkers of lung damage and infection: For what purpose and how should they be used properly? Biomarkers of lung damage can be used for diagnosis, risk stratification/prediction, treatment surveillance and adjustment of targeted therapy. Additionally, novel "omics" methods may offer a completely different and effective way of improving the understanding of pathogenesis of lung damage and a way to develop new candidate lung damage biomarkers. In the current review, we give an overview within the field of acute lung damage of (i) disease mechanism biomarkers, (ii) of "ready to use" evidence-based biomarker-guided lung infection management, (iii) of novel strategies of inflammatory phenotyping and how this can be used to tailor corticosteroid treatment, (iv) a future perspective of where "omics" technologies and mindsets may become increasingly important in developing new strategies for treatment and for understanding the development of acute lung damage.
doi_str_mv 10.3390/jcm8081163
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6722821</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2268938016</sourcerecordid><originalsourceid>FETCH-LOGICAL-c378t-e1c3caf2ca8383657347d9aa948992d2aac6f749061243cdfecb26fecebed0d73</originalsourceid><addsrcrecordid>eNpVUdtqGzEQFaWhCY5f-gFFj6XEiS6blbYPBTfkBoaUxn0WsjRry9mVttKuwSEfH4U4t3mYOTCHM3M4CH2l5JjzipysTSuJpLTkn9ABI0JMCJf88zu8j8YprUkuKQtGxRe0zymX7FSKA_Tw24VWxzuICYcaT83QA54Nfomv_XqIWzxfQYbWbZwddOPuweJp18WgzeonrkPEf1bgQ7_tnF8e4b8u3eHbPure1c7kHjzW3uJ5BN234Ht8O8QNuKbR3sAh2qt1k2C8myP07-J8fnY1md1cXp9NZxPDhewnQA03umZGy2ynPBW8ELbSuipkVTHLtDZlLYqKlJQV3NgazIKVucMCLLGCj9CvZ91uWLRgTf4j6kZ10WXrWxW0Ux833q3UMmxUKRiTjGaB7zuBGP4PkHrVumTgyQWEISnGSllxSXIKI_TjmWpiSClC_XqGEvWUmHpLLJO_vX_slfqSD38E3hWU_w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2268938016</pqid></control><display><type>article</type><title>Biomarkers of Acute Lung Injury The Individualized Approach: for Phenotyping, Risk Stratification and Treatment Surveillance</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Murray, Daniel D ; Itenov, Theis Skovsgaard ; Sivapalan, Pradeesh ; Eklöf, Josefin Viktoria ; Holm, Freja Stæhr ; Schuetz, Philipp ; Jensen, Jens Ulrik</creator><creatorcontrib>Murray, Daniel D ; Itenov, Theis Skovsgaard ; Sivapalan, Pradeesh ; Eklöf, Josefin Viktoria ; Holm, Freja Stæhr ; Schuetz, Philipp ; Jensen, Jens Ulrik</creatorcontrib><description>Do we need biomarkers of lung damage and infection: For what purpose and how should they be used properly? Biomarkers of lung damage can be used for diagnosis, risk stratification/prediction, treatment surveillance and adjustment of targeted therapy. Additionally, novel "omics" methods may offer a completely different and effective way of improving the understanding of pathogenesis of lung damage and a way to develop new candidate lung damage biomarkers. In the current review, we give an overview within the field of acute lung damage of (i) disease mechanism biomarkers, (ii) of "ready to use" evidence-based biomarker-guided lung infection management, (iii) of novel strategies of inflammatory phenotyping and how this can be used to tailor corticosteroid treatment, (iv) a future perspective of where "omics" technologies and mindsets may become increasingly important in developing new strategies for treatment and for understanding the development of acute lung damage.</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><identifier>DOI: 10.3390/jcm8081163</identifier><identifier>PMID: 31382587</identifier><language>eng</language><publisher>Switzerland: MDPI</publisher><subject>Review</subject><ispartof>Journal of clinical medicine, 2019-08, Vol.8 (8), p.1163</ispartof><rights>2019 by the authors. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c378t-e1c3caf2ca8383657347d9aa948992d2aac6f749061243cdfecb26fecebed0d73</citedby><cites>FETCH-LOGICAL-c378t-e1c3caf2ca8383657347d9aa948992d2aac6f749061243cdfecb26fecebed0d73</cites><orcidid>0000-0003-4036-0521</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6722821/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6722821/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31382587$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Murray, Daniel D</creatorcontrib><creatorcontrib>Itenov, Theis Skovsgaard</creatorcontrib><creatorcontrib>Sivapalan, Pradeesh</creatorcontrib><creatorcontrib>Eklöf, Josefin Viktoria</creatorcontrib><creatorcontrib>Holm, Freja Stæhr</creatorcontrib><creatorcontrib>Schuetz, Philipp</creatorcontrib><creatorcontrib>Jensen, Jens Ulrik</creatorcontrib><title>Biomarkers of Acute Lung Injury The Individualized Approach: for Phenotyping, Risk Stratification and Treatment Surveillance</title><title>Journal of clinical medicine</title><addtitle>J Clin Med</addtitle><description>Do we need biomarkers of lung damage and infection: For what purpose and how should they be used properly? Biomarkers of lung damage can be used for diagnosis, risk stratification/prediction, treatment surveillance and adjustment of targeted therapy. Additionally, novel "omics" methods may offer a completely different and effective way of improving the understanding of pathogenesis of lung damage and a way to develop new candidate lung damage biomarkers. In the current review, we give an overview within the field of acute lung damage of (i) disease mechanism biomarkers, (ii) of "ready to use" evidence-based biomarker-guided lung infection management, (iii) of novel strategies of inflammatory phenotyping and how this can be used to tailor corticosteroid treatment, (iv) a future perspective of where "omics" technologies and mindsets may become increasingly important in developing new strategies for treatment and for understanding the development of acute lung damage.</description><subject>Review</subject><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpVUdtqGzEQFaWhCY5f-gFFj6XEiS6blbYPBTfkBoaUxn0WsjRry9mVttKuwSEfH4U4t3mYOTCHM3M4CH2l5JjzipysTSuJpLTkn9ABI0JMCJf88zu8j8YprUkuKQtGxRe0zymX7FSKA_Tw24VWxzuICYcaT83QA54Nfomv_XqIWzxfQYbWbZwddOPuweJp18WgzeonrkPEf1bgQ7_tnF8e4b8u3eHbPure1c7kHjzW3uJ5BN234Ht8O8QNuKbR3sAh2qt1k2C8myP07-J8fnY1md1cXp9NZxPDhewnQA03umZGy2ynPBW8ELbSuipkVTHLtDZlLYqKlJQV3NgazIKVucMCLLGCj9CvZ91uWLRgTf4j6kZ10WXrWxW0Ux833q3UMmxUKRiTjGaB7zuBGP4PkHrVumTgyQWEISnGSllxSXIKI_TjmWpiSClC_XqGEvWUmHpLLJO_vX_slfqSD38E3hWU_w</recordid><startdate>20190803</startdate><enddate>20190803</enddate><creator>Murray, Daniel D</creator><creator>Itenov, Theis Skovsgaard</creator><creator>Sivapalan, Pradeesh</creator><creator>Eklöf, Josefin Viktoria</creator><creator>Holm, Freja Stæhr</creator><creator>Schuetz, Philipp</creator><creator>Jensen, Jens Ulrik</creator><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4036-0521</orcidid></search><sort><creationdate>20190803</creationdate><title>Biomarkers of Acute Lung Injury The Individualized Approach: for Phenotyping, Risk Stratification and Treatment Surveillance</title><author>Murray, Daniel D ; Itenov, Theis Skovsgaard ; Sivapalan, Pradeesh ; Eklöf, Josefin Viktoria ; Holm, Freja Stæhr ; Schuetz, Philipp ; Jensen, Jens Ulrik</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c378t-e1c3caf2ca8383657347d9aa948992d2aac6f749061243cdfecb26fecebed0d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Murray, Daniel D</creatorcontrib><creatorcontrib>Itenov, Theis Skovsgaard</creatorcontrib><creatorcontrib>Sivapalan, Pradeesh</creatorcontrib><creatorcontrib>Eklöf, Josefin Viktoria</creatorcontrib><creatorcontrib>Holm, Freja Stæhr</creatorcontrib><creatorcontrib>Schuetz, Philipp</creatorcontrib><creatorcontrib>Jensen, Jens Ulrik</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Murray, Daniel D</au><au>Itenov, Theis Skovsgaard</au><au>Sivapalan, Pradeesh</au><au>Eklöf, Josefin Viktoria</au><au>Holm, Freja Stæhr</au><au>Schuetz, Philipp</au><au>Jensen, Jens Ulrik</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biomarkers of Acute Lung Injury The Individualized Approach: for Phenotyping, Risk Stratification and Treatment Surveillance</atitle><jtitle>Journal of clinical medicine</jtitle><addtitle>J Clin Med</addtitle><date>2019-08-03</date><risdate>2019</risdate><volume>8</volume><issue>8</issue><spage>1163</spage><pages>1163-</pages><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>Do we need biomarkers of lung damage and infection: For what purpose and how should they be used properly? Biomarkers of lung damage can be used for diagnosis, risk stratification/prediction, treatment surveillance and adjustment of targeted therapy. Additionally, novel "omics" methods may offer a completely different and effective way of improving the understanding of pathogenesis of lung damage and a way to develop new candidate lung damage biomarkers. In the current review, we give an overview within the field of acute lung damage of (i) disease mechanism biomarkers, (ii) of "ready to use" evidence-based biomarker-guided lung infection management, (iii) of novel strategies of inflammatory phenotyping and how this can be used to tailor corticosteroid treatment, (iv) a future perspective of where "omics" technologies and mindsets may become increasingly important in developing new strategies for treatment and for understanding the development of acute lung damage.</abstract><cop>Switzerland</cop><pub>MDPI</pub><pmid>31382587</pmid><doi>10.3390/jcm8081163</doi><orcidid>https://orcid.org/0000-0003-4036-0521</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2077-0383
ispartof Journal of clinical medicine, 2019-08, Vol.8 (8), p.1163
issn 2077-0383
2077-0383
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6722821
source PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Review
title Biomarkers of Acute Lung Injury The Individualized Approach: for Phenotyping, Risk Stratification and Treatment Surveillance
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T20%3A21%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biomarkers%20of%20Acute%20Lung%20Injury%20The%20Individualized%20Approach:%20for%20Phenotyping,%20Risk%20Stratification%20and%20Treatment%20Surveillance&rft.jtitle=Journal%20of%20clinical%20medicine&rft.au=Murray,%20Daniel%20D&rft.date=2019-08-03&rft.volume=8&rft.issue=8&rft.spage=1163&rft.pages=1163-&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/10.3390/jcm8081163&rft_dat=%3Cproquest_pubme%3E2268938016%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2268938016&rft_id=info:pmid/31382587&rfr_iscdi=true